(0.04%) 5 310.29 points
(0.12%) 39 956 points
(-0.05%) 16 734 points
(0.61%) $79.11
(2.86%) $2.49
(-0.41%) $2 385.10
(0.58%) $29.90
(0.01%) $1 070.20
(0.15%) $0.920
(0.29%) $10.70
(0.09%) $0.789
(0.16%) $90.83
@ $5.26
Issued: 14 Feb 2024 @ 14:48
Return: -17.38%
Previous signal: Feb 14 - 09:31
Previous signal:
Return: 2.24 %
Live Chart Being Loaded With Signals
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders...
Stats | |
---|---|
Today's Volume | 527 055 |
Average Volume | 1.95M |
Market Cap | 395.69M |
EPS | $0 ( 2024-05-13 ) |
Next earnings date | ( $-0.290 ) 2024-08-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.97 |
ATR14 | $0.0110 (0.25%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-01 | Carson William H. | Buy | 3 200 | Common Stock |
2024-04-08 | Carson William H. | Buy | 3 200 | Common Stock |
2024-02-16 | Love Douglas | Buy | 656 200 | Stock Option (Right to Buy) |
2024-02-16 | Dananberg Jamie | Buy | 160 000 | Stock Option (Right to Buy) |
2024-02-16 | Dananberg Jamie | Buy | 39 000 | Common Stock |
INSIDER POWER |
---|
80.76 |
Last 94 transactions |
Buy: 9 091 580 | Sell: 849 119 |
Volume Correlation
Annexon, Inc. Correlation
10 Most Positive Correlations | |
---|---|
GTHX | 0.93 |
STKL | 0.913 |
NUTX | 0.91 |
DXCM | 0.91 |
EYE | 0.91 |
SDG | 0.909 |
EAR | 0.908 |
SVOK | 0.907 |
RRGB | 0.906 |
RTPY | 0.906 |
10 Most Negative Correlations | |
---|---|
HDSN | -0.916 |
LCA | -0.9 |
DISH | -0.897 |
MDWT | -0.896 |
RMRM | -0.893 |
NVCN | -0.89 |
SENEA | -0.885 |
OHAA | -0.882 |
HNRG | -0.879 |
ROKU | -0.878 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Annexon, Inc. Correlation - Currency/Commodity
Annexon, Inc. Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-3.27M (0.00 %) |
EPS: | $-1.770 |
FY | 2023 |
Revenue: | $0 |
Gross Profit: | $-3.27M (0.00 %) |
EPS: | $-1.770 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $-3.31M (0.00 %) |
EPS: | $-2.53 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-7.68 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators